UNSPSC 51162704: Bromhexine

This classification denotes an expectorant with the molecular formula C14H20Br2N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) Q1J152VB1P, chemically known as 3,5-dibromo-nalpha-cyclohexyl-nalpha-methyltoluene-alpha-2-diamine but more generally known as bromhexine, which bears US NIH Compound Identifier 2442. Bromhexine most often comes in base, chloride, and hydrochloride forms. European Medicines Agency schedules Bromhexine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05914MIG.

UNSPSC 51162704 Bromhexine, a Commodity code, maps poorly to the actual state and local pharmaceutical procurement activity appearing in recent solicitations. The code nominally covers a single active pharmaceutical ingredient used in respiratory treatments, but recent opportunities under this classification involve broader pharmaceutical supply arrangements — naloxone procurement for opioid overdose response and multi-source generic pharmaceuticals distributed through cooperative purchasing vehicles — that do not center on bromhexine products. State and local health departments and cooperative purchasing alliances are the primary issuing bodies, but the mismatch between the code's narrow scope and the actual solicitation content suggests either tagging errors or that bromhexine itself sees minimal procurement activity at the state and local level.

The geographic spread of recent activity spans Florida and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) representing multi-state reach across participating jurisdictions including Oregon. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, response due July 26, 2023. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products supplied through three authorized wholesalers, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The code shows limited recent relevant activity, and procurement professionals evaluating this classification should verify coding against actual pharmaceutical line items before committing resources.